Cancer treatment and survivorship statistics, 2025
2025/05/30 by Nikita Sandeep Wagle, Letícia Nogueira, Leticia Nogueira +8 · 29 citations
Medicine · #Global Cancer Incidence and Screening #Multiple and Secondary Primary Cancers #Cancer survivorship and care
paper · pdf · doi:10.3322/caac.70011
Abstract
The number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the population as well as improved survival through advances in early detection and treatment. To assist the public health community serve the needs of these survivors, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using data from the Surveillance, Epidemiology, and End Results cancer registries, the Centers for Disease Control and Prevention's National Center for Health Statistics, and the United States Census Bureau. In addition, cancer treatment patterns are presented from the National Cancer Database along with a brief overview of treatment-related side effects. As of January 1, 2025, about 18.6 million people were living in the United States with a history of cancer, and this number is projected to exceed 22 million by 2035. The three most prevalent cancers are prostate (3,552,460), melanoma of the skin (816,580), and colorectum (729,550) among males and breast (4,305,570), uterine corpus (945,540), and thyroid (859,890) among females. About one half (51%) of survivors were diagnosed within the past 10 years, and nearly four fifths (79%) were aged 60 years and older. Racial differences in treatment in 2021 were common across disease stage; for example, Black people with stage I-II lung cancer were less likely to undergo surgery than their White counterparts (47% vs. 52%). Larger disparities exist for rectal cancer, for which 39% of Black people with stage I disease undergo proctectomy or proctocolectomy compared to 64% of their White counterparts. Targeted, multi-level efforts to expand access to high-quality care and survivorship resources are vital to reducing disparities and advancing support for all survivors of cancer.
Citations
Cited by
- Health-related quality of life domains relevant to people in Europe undergoing cancer treatment: a systematic review of qualitative research
- Colorectal cancer statistics, 2026
- Land use, zoning, and breast cancer incidence in California: an ecological study
- Leisure-Time Physical Activity and Cancer Mortality Among Cancer Survivors
- Cancer treatment and survivorship statistics, 2025: An urgent call to optimize health after cancer. [europepmc]
- Survivorship Challenges and Supportive Care in Lung Cancer. [europepmc]
- Defining Family-Centered Cancer Care: A Group Concept Mapping Study. [europepmc]
- Self-efficacy for cancer self-management in the context of COVID-19: a cross-sectional survey study. [europepmc]
- FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation. [europepmc]
- Integrating bulk RNA-seq, scRNA-seq, and spatial transcriptomics data to identify novel post-translational modification-related molecular subtypes and therapeutic responses in hepatocellular carcinoma. [europepmc]
- Federal Housing Assistance and Stage at Cancer Diagnosis Among Older Adults in the US. [europepmc]
- NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study. [europepmc]
- Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a. [europepmc]
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer. [europepmc]
- CircATP2C1 Drives Prostate Cancer Progression Through miR-654-3p-Mediated SLC7A11 Upregulation and Ferroptosis Suppression. [europepmc]
- Dietary patterns, polygenic risk, and kidney cancer incidence: a UK Biobank cohort study. [europepmc]
- Endometrial cancer therapy in 2026. [europepmc]
- A Vision Toward Risk-Stratified Postoperative Surveillance for Lung Cancer: Harnessing CT and AI. [europepmc]
- Computational fluid dynamics modeling and simulation of nanoparticle-tumor interaction: Systematic literature review. [europepmc]
- Hyperbaric oxygen therapy for chronic radiotherapy-related adverse effects: A clinically focused review. [europepmc]
- Covalent organic framework-based electrochemical nanosensing: an emerging paradigm for early cancer diagnosis and longitudinal surveillance. [europepmc]
- Classic Protocadherin PCDH10 Functions as a Tumor Suppressive Scaffold Protein Antagonizing Oncogenic WNT/β-catenin Signaling in Breast Carcinogenesis. [europepmc]
- Associations of fine particulate matter pollution components with overall, prostate cancer, and cardiovascular disease mortality in men with prostate cancer: A cohort study. [europepmc]
- What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors. [europepmc]
- Leisure-Time Physical Activity and Cancer Mortality Among Cancer Survivors. [europepmc]
- Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions. [europepmc]
- A pH-Sensitive Sprayable Fluorescent Probe Enables Accurate Visualization of Thyroid Cancer Margins for Fluorescence-Guided Surgery in Orthotopic Mouse Models. [europepmc]
- Colorectal cancer statistics, 2026. [europepmc]
- Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer. [europepmc]
Related